Recon: GSK, Sanofi in talks for £500M UK coronavirus vaccine deal; Regeneron begins Phase 2/3 trial for COVID-19 antibody cocktail

• White House teases executive orders on China, immigration and prescription drugs (Politico)
• Regeneron starts COVID-19 antibody cocktail late-stage trials, shares rise (Reuters) (Press)
• 2021 Health Plans Granted Leeway To Limit Consumers’ Benefit From Drug Coupons (KHN)
• FDA Commissioner Stephen Hahn won’t confirm Trump’s promises on vaccine timing (ABC)
• Trial of Moderna Covid-19 vaccine delayed, investigators say, but July start still possible (STAT)
• FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals (Endpoints)
• ViiV gets FDA nod for Rukobia drug for older HIV patients (PharmaPhorum) (Press)
• Which drug developers offer Trump a quick, game-changing ‘solution’ as the pandemic roars back? Eli Lilly and AbCellera look to break out of the pack (Endpoints)
• Pharma industry seizes on pandemic as a shot at redemption (Financial Times)
• House spending bill counters Trump threat to cut WHO funding (The Hill)
• Federal Circuit Denies Genentech’s Appeal to Block Sales of Amgen’s MVASI (Big Molecule Watch)

• UK in talks to join EU coronavirus vaccine plan (Financial Times)
• Glaxo Smith Kline nears £500m UK coronavirus vaccine deal (The Times) (Bloomberg)
• Australia’s CSL warns drugmakers not to rush Covid-19 vaccine (Financial Times)
• Mylan to launch generic remdesivir version in India at $64 per 100 mg vial (Reuters)
• India scientists alarmed over 'unrealistic' Covid vaccine deadline (BBC)
• Gilead's COVID-19 antiviral remdesivir gets conditional EU clearance (Reuters)
• WHO halts hydroxychloroquine, HIV drugs in COVID trials after failure to reduce death (Reuters) (WHO)
• Tesla to make molecule printers for German COVID-19 vaccine developer CureVac (Reuters)
• Repurpose.AI partnered with LEO Pharma to accelerate drug discovery (Business Insider)
• WHO: access to HIV medicines severely impacted by COVID-19 as AIDS response stalls (WHO)

• 239 Experts With One Big Claim: The Coronavirus Is Airborne (NYTimes)
• Why the US still hasn't solved its testing crisis (Politico)
• US Should Build Up Antibody Therapy Supply, Ex-FDA Chief Says (Bloomberg)
• CDC gets FDA nod for coronavirus-flu combination diagnostic (MedtechDive)
• BD launches coronavirus antigen test, 2nd to get FDA emergency use authorization (MedtechDive)
• US Coronavirus Cases Are Rising Sharply, but Deaths Are Still Down (NYTimes)
• The Pandemic’s Big Mystery: How Deadly Is the Coronavirus? (NYTimes)
• Phoenix Mayor Says FEMA Refused to Help With Testing (NYTimes)
• DNA Linked to Covid-19 Was Inherited From Neanderthals, Study Finds (NYTimes)
• UK study to research long-term health impact of COVID-19 (PharmaTimes)
• Data show panic and disorganization dominate the study of Covid-19 drugs (STAT)
• How a Covid-19 Vaccine Could Cost Americans Dearly (NYTimes)
• How Much Would Coronavirus Vaccine Cost? (NPR)

• Immunomedics’ breast cancer drug delays tumor growth, prolongs survival in clinical trial (STAT)
• Bellus Health suffers setback with clinical trial failure of chronic cough drug (STAT) (Endpoints)
• Stacked User Fee Calendar Puts Another Record-Setting Year For US FDA Novel Approvals Within Reach (Pink Sheet)
• Pfizer re-ups on Mission Therapeutics collaboration, leading a $15M round and grabbing first dibs on DUBs (Endpoints)
• A little biotech slaps back at a 'criminal' short attack, vowing to pursue a prosecution of their case (Endpoints)
• Poseida tees $150M IPO; Gilead sends HBV program back to Precision; New HIV data from Merck, Gilead (Endpoints)
• A booming Dragonfly is taking its TriNKETs to Copenhagen as the latest Bristol Myers pact spurs expansion plans — outside the US (Endpoints)
• IPO bound? Actually, Annexon was already prepped and primed to toss its S-1 to Wall Street as investors rallied (Endpoints)
• Immunomedics spells out PFS benefit of Trodelvy in mTNBC, hunting a full OK just weeks after accelerated approval (Endpoints)
• ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills (Endpoints)
• Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper(PharmaJapan)

• Endologix files for Ch. 11 bankruptcy, plans to go private (MedtechDive)
• Commission Notified Body Survey For COVID-19 Products Falls Short On Detail (MedtechInsight)
• How a device shelved for health reasons in France remained in use in US (Miami Herald) (MassDevice)
• Abbott Trifecta / Trifecta GT bioprosthetic aortic heart valves: cases of structural valve deterioration (SVD) (MDA/2020/019) (MHRA)

• Talking MDL Post-Remand Blues (Drug & Device Law)